Hypersensitivity to nonsteroidal anti-inflammatory drugs

Authors

  • Joanna Glück Z Katedry i Kliniki Chorób Wewnętrznych, Alergologii i Immunologii Klinicznej Śląskiego Uniwersytetu Medycznego

Keywords:

bronchial asthma, cyclooxygenase, nonsteroid anti-inflammatory drugs, hypersensitivity, urticaria/ angioedema

Abstract

Nonsteroid anti-inflammatory drugs (NSAIDs) are one of the most frequently prescribed group of medicines. Their safety profile is poor as they can induce several dangerous side effects and hypersensitivity. In this paper historical aspects, an up-to-date classification of hypersensitivity reactions, patomechanism, clinical presentation and diagnostic procedures have been described. Management of patients sensitive to NSAIDs has been discussed, as well.

Downloads

Download data is not yet available.

References

Hirschberg. Mittheilung uber einen Fall von Neiberwirkkung des Aspirin. Deutsch. Med. Wschr. 1902:28:416.

Gilbert GB. Unusual idiosyncrasy to aspirin. JAMA 1911;56:1262.

Widal MF, Abrami P, Lermeyez J. Anaphylaxie et idiosyn- crasie. Presse Med. 1922;30:189–92.

Samter M, Beers RF. Concerning the nature of the intolerance to aspirin. J. Allergy 1967;40:281–93.

Samter M, Beers R Jr. Intolerance to aspirin: clinical studies and consideration of its pathogenesis. Ann. Intern. Med. 1968;68:975–83.

Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971;231:232–234.

Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Relation- ship of inhibition of prostaglandyn biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. Br. Med. J. 1975;1:67–69.

Szczeklik A. Aspirin-induced asthma: a tribute to John Vane as a source of inspiration. Pharmacol. Rep. 2010;62:526-529

Halpern B, Holzer A, Liacopoulust P, Meyer J. Allergy to pyrazolne derivates (aminopiryne) with evidence of reaginic type antibody. J. Allergy 1958; 29:1–12.

K. Ishizaka, T. Ishizaka. Physicochemical properties of reagi- nic antibody. 3. Further studies on the reaginic antibody in gamma-A-globulin preparations. J. Allergy 1966;38:108–119.

Johansson SG. IgE in allergic diseases. Proc. R. Soc. Med. 1969;62:975–976.

Niżankowska-Mogilnicka i wsp. EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensi- tivity. Allergy 2007;62:1111–1118.

Kowalski LM, Makowska J, Blanca M, Babek S, Boche- nek G, Bousquet J i wsp. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) – classification, diagnosis and management: review of the EAACI/ENDA and GA2LEN/ HANNA. Allergy 2011;66:818–829.

Johansson SGO, O’B Hourihane J, Bousquet J, Bruinzeel- -Koomen C, Dreborg S, Haahtela T i wsp. Nomenclature. Allergy 2001;56:813–824.

Szczeklik A., Niżankowska-Mogilnicka E, Sanak M. Hyper- sensitivity to aspirin and other NSAIDs: Mechanisms, clinical presentation and management. [w:] Pichler WJ (ed): Drug Hypersensitivity, Basel, Karger, 2007;340–349.

Sampson AP, Cowburn AS, Sladek K, Adamek L, Nizankow- ska E, Szczeklik A, Lam BK, Penrose JF, Austen KF, Holga- te ST. Profound overexpression of leukotriene C4 synthase in bronchial biopsies from aspirin-intolerant asthmatic patients. Int. Arch. Allergy Immunol. 1997;113:355–7.

Sanak M, Simon HU, Szczeklik A. Leukotriene C4 synthase promotor polymorphism and risk of aspiryn-induced asthma. Lancet. 1997;350:1599–600.

Sanak M, Szczeklik A. Genetics of aspirin induced asthma. Thorax 2000; 55: supl. 2:S45–7.

Czerniawska-Mysiak, Szczeklik A. Idiosyncrasy to pyraso- lone drugs. Allergy 1981;36:381–384.

Canto MG, Andreu I, Fernandez J, Blanca M. Selective im- mediate hypersensitivity reactions to NSAIDs. Curr. Opin. Allergy Clin. Immunol. 2009;9:293–297.

Pichler W. Drug hypersensitivity reactions: classification and relationship to T-cell activation. W: Pichler WJ. (ed.). Drug Hypersensitivity. Basel. Karger. 2007:168–189.

Pichler W. Delayed drug hypersensitivity reactions. Ann. Intern. Med. 2003;139:683–693.

Berges-Gimeno MP, Simon RA, Stevenson DD. The natural history and clinical characteristics of aspiryn-exacerbated respiratory disease. Ann. Allergy Asthma Immunol. 2002;89:474–478.

Settipane GA, Chafee FH, Klein DE. Aspirin intolerance II. A prospective study in an atopic and normal population. J Allergy Clin. Immunol. 1974;53:200–204.

Hedman J, Kaprio J, Poussa T, Nieminen MM. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int. J. Epidemiol. 1999;28:717–722.

Szczeklik A, Niżankowska E, Duplaga M, on behalf of the AIANE Investigators Natural history of aspirin-induced asthma. Eur. Respir. J. 2000;16:432–436.

Pierzchalska M, Mastalerz L, Sanak M, Zazula M, Szcze- klik A. A moderate and unspecific release of cysteinyl leuko- trienes by aspirin from peripheral blood leukocytes precludes its value for aspirin sensitivity testing in asthma. Clin. Exp. Allergy 2000:30:1785–1791.

Celik G, Babek S, Misirligil Z, Melli M. Release of cysteinyl leukotrienes with aspirin stimulation and the effect of prosta- glandin E(2) on this release from peripheral blood leukocytes in aspirin-induced asthmatic patients. Clin. Exp. Allergy 2001;31:1615–1622.

Gamboa P, Sanz ML, Caballero MR, Urrutia I, Antepara I, Esparza R, de Weck AL. The flow-cytometric determination of basophil activation induced by aspirin and other non- steroidal anti-inflammatory drugs (NSAIDs) is useful for in vitro diagnosis of the NSAID hypersensitivity syndrome. Clin. Exp. Allergy 2004;34:1448–57.

Kowalski ML, Ptasinska A, Jędrzejczak M, Bienkiewicz B, Cieślak M, Grzegorczyk J. Aspirin-triggered 15-HETE generation in peripheral blood leukocytes is a specific and sensitive Aspirin-Sensitive Patients Identification Test (ASPIT- est). Allergy 2005;60:1139–45.

Abuaf N, Rostane H, Barbara J, Toly-Ndour C, Gaouar H, Mathelier-Fusade P i wsp. Comparison of CD63 Upregula- tion Induced by NSAIDs on Basophils and Monocytes in Patients with NSAID Hypersensitivity. J. Allergy (Cairo) 2012;2012:580–873.

Astma aspirynowa. Raport Panelu Ekspertów Polskiego Towarzystwa Alergologicznego i Polskiego Towarzystwa Chorób Płuc w sprawie postępowania w astmie oskrzelowej. W: Wytyczne Polskiego Towarzystwa Alergologicznego i Polskiego Towarzystwa Chorób Płuc dotyczące postępo- wania w astmie oskrzelowej. Wydanie II, Warszawa 2008.

Kowalski ML, Makowska J. Use of non-steroidal anti-in- flammatory drugs in patients with aspirin-hypersensitivity: safety of cyclo-oxygenase-2 inhibitors. Treat. Respir. Med. 2006;5:399–406.

Bavbek S, Celik G, Ozer F, Mingan D, Misirligil Z. Safety of selective COX-2 inhibitors in aspirin/nonsteroidal antiinflammatory drug-intolerant patients: comparison of nime- sulide, meloxicam, and rofecoxib. J. Asthma 2004;41:67–75.

Szczeklik A, Sanak M, Niżankowska-Mogilnicka E, Kiełba- sa B. Aspirin intolerance and the cyclooxygenase-leukotriene pathways. Curr. Opin. Pulm. Med. 2004;10:51–56.

Setkowicz M, Mastalerz L, Podolec-Rubis M, Sanak M, Szczeklik A. Hypersensitivity to aspirin: common eicosa- noid alternations in urticaria and asthma. J. Allergy Clin. Immunol. 2009;123:174–178.

Zuberbier T, Asero R, Bindslev-Jensen C, Canonica W, Church MK, Gimenez-Arnau AM I wsp. EAACI/GA2LEN/ EDF/WAO guideline: management of urticaria. Allergy 2009;64:1427–1443.

Quiralte J, Blanco C, Delgado J, Ortega N, Alentara M, Castillo R i wsp. Challenge-based clinical pattern of 223 Spanish patients with non-steroidal anti-inflammatory- drug-induced-reactions. J. Investig. Allergol. Clin. Immunol. 2007;17:182–188 .

Ravnskov U. Glomerular, tubular and interstitial nephritis associated with non-steroidal anti-inflammatory drugs. Evidence of a common mechanism. Br. J. Clin. Pharmacol. 1999;47:203–210.

Górski P, Szmit M, Bogacka E, Samoliński B, Gotlib T, Ku- rek M i wsp. Próby prowokacji. W: Kruszewski J. Kowalski M. (red.). Standardy w alergologii. cz. I. wydanie II, Kraków 2010.

Société Française d’Anesthésie et de Réanimation. Preven- tion Du Risque Allergique Peranesthesique. www.sfar.org/ allergiefr.html.

Campi P, Manfredi M, Severino M. IgE-mediated allergy to pyrazolones, quinolones and other non--lactam antibiotics. W: Pichler WJ. (ed.). Drug Hypersensitivity. Basel, Karger, 2007;216–232.

Brockow K, Romano A, Blanca K, Ring J, Pichler W, De- moly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 2002;57:45–51.

Barbaud A. Place of drug skin tests in investigating systemic cutaneous drug reactions. W: Pichler WJ. (ed.). Drug Hy- persensitivity. Basel, Karger. 2007;352–365.

Beeler A, Pichler WJ. In vitro tests of T-cell-mediated drug hypersensitivity. W: Pichler WJ. (ed.). Drug Hypersensitivity. Basel, Karger. 2007;380–390.

Aberer W, Bircher A, Romano A, Blanca M, Campi P, Fernandez J i wsp. Drug provocation testing in the diagnosis of drug hypersenstivity reactions: general considerations. Al- lergy 2003;58:854–863.

Stevenson DD. Aspirin desensitization in patients with AERD. Clin. Rev. Allergy Immunol. 2003; 24:159–68.

Stevenson DD, Lee RU. Aspirin-exacerbated respiratory disease: evaluation and management. Allergy Asthma Immunol. Res. 2011;3:3–10.

Buhl T, Meynberg H, Kaune K, Hünecke P, Schön M, Fuchs T. Long-term follow-up of patients with hypersensitivity to nonsteroidal anti-inflammatory drugs reveals shortco- mings in compliance and care. J. Allergy Clin. Immunol. 2011;127:284–285.

Downloads

Published

2012-06-30

How to Cite

Glück, J. (2012). Hypersensitivity to nonsteroidal anti-inflammatory drugs. European Journal of Clinical and Experimental Medicine, 10(2), 157–166. Retrieved from https://journals.ur.edu.pl/ejcem/article/view/12742

Issue

Vol. 10 No. 2 (2012): Medical Journal of the Rzeszow University and the National Medicines Institute, Warsaw

Section

EDITORIAL REMARKS

License

Copyright (c) 2012 Medical Journal of the Rzeszow University and the National Medicines Institute, Warsaw

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.

All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.